Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

NCT03609840 · clinicaltrials.gov ↗

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies
Nonmalignant Diseases
Immune Deficiency
Hemoglobinopathies
Genetic Inborn Errors of Metabolism
Fanconi Anemia
Thalassemia
Sickle Cell Disease

Interventions

DRUG: Thiotepa

Sponsor

University of California, San Francisco